Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: A comparative analysis in nephrology, diabetology and primary care settings

Journal of Hypertension

Volumn 24, Issue 8, 2006, Pages 1655-1661

  Minutolo, Roberto ^a   Sasso, Ferdinando C ^a   Chiodini, Paolo ^a   Cianciaruso, Bruno ^b   Carbonara, Ornella ^a   Zamboli, Pasquale ^a   Tirino, Giuseppina ^a   Pota, Andrea ^b   Torella, Roberto ^a   Conte, Giuseppe ^a   Nicola, Luca De ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cardiovascular risk; Chronic kidney disease; Diabetic nephropathy; Dyslipidaemia; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FUROSEMIDE; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFICACY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SODIUM RESTRICTION;

EID: 33746764463     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000239303.93872.31     Document Type: Article

References (33)

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28 (Suppl. 1):S4-S36.
2. National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1):S1-S266.
3. Patel UD, Young EW, Ojo AO, Hayward RA. CKD progression and mortality among older patients with diabetes. Am J Kidney Dis 2005; 46:406-414.
4. Dikow R, Ritz E. Cardiovascular complications in the diabetic patient with renal disease: an update in 2003. Nephrol Dial Transplant 2003; 18:1993-1998.
5. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, on behalf of the UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63:225-232.
6. Ruggenenti P, Remuzzi G. Nephropathy of type-2 diabetes mellitus. J Am Soc Nephrol 1998; 9:2157-2169.
7. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004; 66:1596-1605.
8. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, et al., for the RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int 2003; 63:1499-1507.
9. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393.
10. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34:795-808.
11. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, et al., on behalf of the QuED Study Group. Quality of care and outcomes in type 2 diabetic patients: a comparison between general practice and diabetes clinics. Diabetes Care 2004; 27:398-406.
12. Greenfield S, Kaplan SH, Kahn R, Ninomiya J, Griffith JL. Profiling care provided by different groups of physicians: effects of patient case-mix (bias) and physician-level clustering on quality assessment results. Ann Intern Med 2002; 136:111-121.
13. Wong TYH, Choi PCL, Szeto CC, To KF, Tang NLS, Chan AWH, et al. Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies. Diabetes Care 2002; 25:900-905.
14. National Cholesterol Education Program Expert panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 1285:2486-2497.
15. Rigalleau V, Lasseur C, Perlemoine C, Barthe N, Raffaitin C, Liu C, et al. Estimation of glomerular filtration rate in diabetic subjects. Cockroft formula or Modification of Diet in Renal Disease study equation? Diabetes Care 2005; 28:838-843.
16. Burton P, Gurrin L, Sly P. Extending the simple linear regression model to account for correlated responses: an introduction to generalized estimating equation and multi-level mixed modeling. Stat Med 1998; 17:1261-1291.
17. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, epidemiology and prevention. Circulation 2003; 108:2154-2169.
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
19. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-696.
20. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
21. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, et al. for the ASCOT Investigators. Reduction in cardiovascular events with atorvastatin in 2, 532 patients with type 2 diabetes. Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 2005; 28:1151-1157.
22. Fioretto P, Mauer M, Brocco E, Velusi M, Frigato F, Muotto B, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996; 39:1569-1575.
23. De Nicola L, Minutolo R, Bellizzi V, Zoccali C, Cianciaruso B, Andreucci VE, et al., for the investigators of the TArget Blood Pressure LEvels in Chronic Kidney Disease (TABLE in CKD) Study Group. Achievement of target blood pressure levels in chronic kidney disease: a salty question ? Am J Kidney Dis 2004; 43:782-795.
24. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36:646-661.
25. Brater DC. Diuretic therapy. N Engl J Med 1998; 339:387-395.
26. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335-342.
27. Grant RW, Buse JB, Meigs JB, for the University Healthsystem Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. Academic Medical Centers. Low rates of medical regimen change. Diabetes Care 2005; 28:337-442.
28. Beaton SJ, Nag SS, Gunter MJ, Gleeson JM, Sajjan SS, Alexander CM. Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care setting. Diabetes Care 2004; 27:694-698.
29. McFarlane SI, Jacober SJ, Winer N, Kaur J, Castro JP, Wui MA, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at Urban Academic Medical Centers. Diabetes Care 2002; 25:718-723.
30. Craig KJ, Donovan K, Munnery M, Owens DR, Williams JD, Phillips AO. Identification and management of diabetic nephropathy in the diabetes clinic. Diabetes Care 2003; 26:1806-1811.
31. Grant RW, Cagliero E, Dubey AK, Gildesgame C, Chueh HC, Barry MJ, et al. Clinical inertia in the management of type 2 diabetes metabolic risk factors. Diabet Med 2004; 21:150-155.
32. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16:529-538.
33. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease. Comparison of traditional and novel risk factors. JAMA 2005; 293:1737-1745.